Priorities for testing and choosing combination therapies in rhabdoid tumors to guide clinical trials
Official title: PRIORITIES: PReclinical evaluation and prIORITisation of novel combinations in Rhabdoid Tumours leading to rational clinical studies
Funded at Sloan-Kettering Inst Can Research · NIH-11570539 · Data updated 2026-11-12
A coordinated, multi-site effort will rigorously test promising drug combinations in rhabdoid tumors to identify the most promising options for future patient trials.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 1, 2026 |
| Project end | August 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $1,500,000 |
| NIH project number | 1U01FD008985-01 |
| Project ID | NIH-11570539 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with rhabdoid tumors (including ATRT and extracranial malignant rhabdoid tumors) or their samples may benefit from future trials informed by this work.
✕Less likely to help
This grant is preclinical; individual patients would not receive a therapy from participation in the research itself.
What this research studies
This project creates a shared, international preclinical testing platform for rhabdoid tumors, including ATRT and extracranial rhabdoid cancers. It uses standardized lab procedures and a federated model resource to compare many treatment combinations across tumor subtypes. The goal is to pinpoint which combinations should move forward to clinical testing, given the rarity and heterogeneity of these cancers. The work is led by Sloan Kettering with St. Jude and Nationwide Children’s Hospital coordinating the testing at multiple sites.
Why it matters
Potential benefit: If successful, patients with rhabdoid tumors could gain access to more promising, properly prioritized treatment options in future trials.
How similar studies have gone: Previous multi-site preclinical platforms have helped prioritize therapies for rare cancers, though this exact rhabdoid-focused consortium is a novel, targeted effort.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Dela Cruz, Filemon S — Sloan-Kettering Inst Can Research
- Study coordinator: Dela Cruz, Filemon S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.